drugset / Trial / NCT02667275

A Randomized, Double-Blind, Vehicle-Controlled Study in Subjects With Seborrheic Keratosis

NCT02667275

Phase 3 Completed 487 enrolled Aclaris Therapeutics, Inc.
RandomizedParallel-groupDouble-blindTreatment

Summary

This is a randomized, double-blind, vehicle-controlled, parallel group study.

Timeline

Start
2016-01
Primary completion
2016-10
Completion
2016-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Hydrogen Peroxide Small molecule 40 % Topical

Indications